| 69.11 1.83 (2.72%) | 07-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 83.5 |
1-year : | 97.52 |
| Resists | First : | 71.48 |
Second : | 83.5 |
| Pivot price | 68.19 |
|||
| Supports | First : | 67.67 |
Second : | 65.31 |
| MAs | MA(5) : | 67.77 |
MA(20) : | 68.08 |
| MA(100) : | 70.84  |
MA(250) : | 75.71 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 37.8 |
D(3) : | 30.6 |
| RSI | RSI(14): 54.6 |
|||
| 52-week | High : | 90.46 | Low : | 61.83 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ALC ] has closed below upper band by 32.1%. Bollinger Bands are 41.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 69.89 - 70.23 | 70.23 - 70.53 |
| Low: | 67.5 - 67.89 | 67.89 - 68.23 |
| Close: | 68.52 - 69.13 | 69.13 - 69.65 |
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Mon, 27 Jul 2026
ALC|Alcon AG|Price:69.125|Chg%:+1.845 - TradingKey
Fri, 24 Jul 2026
Alcon (ALC) Unveils Advanced Training Center for Vitreoretinal S - GuruFocus
Tue, 21 Jul 2026
A Look at Alcon Inc (ALC) After 3.8% Decline -- GF Value $91.41 vs Price $67.35 - GuruFocus
Mon, 20 Jul 2026
Alcon Inc. (ALC) Stock Analysis: Navigating 24.66% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Wed, 08 Jul 2026
Is Alcon (SWX:ALC) Undervalued After Its RxSight Collaboration? - Yahoo Finance
Wed, 08 Jul 2026
Can Alcon Inc. (ALC) Stock Rebound as New Eye Care Products Approach Regulatory Milestones? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Specialties
|
|
| Shares Out | 488 (M) |
| Shares Float | 486 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 66.3 (%) |
| Shares Short | 10,390 (K) |
| Shares Short P.Month | 8,620 (K) |
| EPS | 1.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 45.38 |
| Profit Margin | 7.6 % |
| Operating Margin | 12.1 % |
| Return on Assets (ttm) | 2.5 % |
| Return on Equity (ttm) | 3.7 % |
| Qtrly Rev. Growth | 9.3 % |
| Gross Profit (p.s.) | 12.24 |
| Sales Per Share | 21.79 |
| EBITDA (p.s.) | 4.73 |
| Qtrly Earnings Growth | -44.6 % |
| Operating Cash Flow | 2,300 (M) |
| Levered Free Cash Flow | 1,230 (M) |
| PE Ratio | 41.38 |
| PEG Ratio | 1.5 |
| Price to Book value | 1.52 |
| Price to Sales | 3.17 |
| Price to Cash Flow | 14.65 |
| Dividend | 0.36 |
| Forward Dividend | 0 |
| Dividend Yield | 0.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|